Literature DB >> 8186692

Interaction of synaptotagmin with voltage gated calcium channels: a role in Lambert-Eaton myasthenic syndrome?

P David1, N Martin-Moutot, C Leveque, O el Far, M Takahashi, M J Seagar.   

Abstract

Plasma from patients with Lambert-Eaton myasthenic syndrome (LEMS), an autoimmune disease of neuromuscular transmission, contains antibodies that bind to the synaptic vesicle protein synaptotagmin. Synaptotagmin associates with calcium channels and appears to regulate synaptic vesicle docking at the plasma membrane prior to rapid neurotransmitter release. Autoantibodies directed against a synaptotagmin-calcium channel complex may be involved in the etiology of LEMS. In the majority of patients LEMS is associated with small cell lung cancer (SCLC). We have detected the expression of proteins of the secretory pathway, including synaptotagmin, syntaxin and N-type calcium channels, in a panel of SCLC tumor lines. These observations are compatible with the hypothesis that the initial autoimmune response in LEMS is triggered by the tumor.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8186692     DOI: 10.1016/0960-8966(93)90095-2

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  3 in total

Review 1.  Ca2+ channels as targets of neurological disease: Lambert-Eaton Syndrome and other Ca2+ channelopathies.

Authors:  Michael T Flink; William D Atchison
Journal:  J Bioenerg Biomembr       Date:  2003-12       Impact factor: 2.945

2.  Retinal glycoprotein enrichment by concanavalin a enabled identification of novel membrane autoantigen synaptotagmin-1 in equine recurrent uveitis.

Authors:  Margarete E Swadzba; Stefanie M Hauck; Hassan Y Naim; Barbara Amann; Cornelia A Deeg
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240

Review 3.  Neuroimmunotoxicology: humoral assessment of neurotoxicity and autoimmune mechanisms.

Authors:  H A El-Fawal; S J Waterman; A De Feo; M Y Shamy
Journal:  Environ Health Perspect       Date:  1999-10       Impact factor: 9.031

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.